R2AR34 logo

Ultragenyx Pharmaceutical BOVESPA:R2AR34 Stock Report

Last Price

R$30.57

Market Cap

R$25.1b

7D

0%

1Y

35.0%

Updated

24 Dec, 2024

Data

Company Financials +

Ultragenyx Pharmaceutical Inc.

BOVESPA:R2AR34 Stock Report

Market Cap: R$25.1b

R2AR34 Stock Overview

A biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. More details

R2AR34 fundamental analysis
Snowflake Score
Valuation3/6
Future Growth2/6
Past Performance0/6
Financial Health2/6
Dividends0/6

My Notes

Capture your thoughts, links and company narrative

Ultragenyx Pharmaceutical Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Ultragenyx Pharmaceutical
Historical stock prices
Current Share PriceUS$30.57
52 Week HighUS$33.03
52 Week LowUS$21.64
Beta0.55
1 Month Change0%
3 Month Changen/a
1 Year Change35.03%
3 Year Changen/a
5 Year Changen/a
Change since IPO-17.36%

Recent News & Updates

Recent updates

Shareholder Returns

R2AR34BR BiotechsBR Market
7D0%-2.9%-3.2%
1Y35.0%-1.7%-13.0%

Return vs Industry: R2AR34 exceeded the BR Biotechs industry which returned -1.7% over the past year.

Return vs Market: R2AR34 exceeded the BR Market which returned -13% over the past year.

Price Volatility

Is R2AR34's price volatile compared to industry and market?
R2AR34 volatility
R2AR34 Average Weekly Movementn/a
Biotechs Industry Average Movement9.2%
Market Average Movement5.0%
10% most volatile stocks in BR Market9.5%
10% least volatile stocks in BR Market2.9%

Stable Share Price: R2AR34's share price has been volatile over the past 3 months compared to the BR market.

Volatility Over Time: Insufficient data to determine R2AR34's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
20101,276Emil Kakkiswww.ultragenyx.com

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company’s products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III.

Ultragenyx Pharmaceutical Inc. Fundamentals Summary

How do Ultragenyx Pharmaceutical's earnings and revenue compare to its market cap?
R2AR34 fundamental statistics
Market capR$25.07b
Earnings (TTM)-R$3.46b
Revenue (TTM)R$3.24b

7.7x

P/S Ratio

-7.2x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
R2AR34 income statement (TTM)
RevenueUS$522.75m
Cost of RevenueUS$720.33m
Gross Profit-US$197.59m
Other ExpensesUS$361.40m
Earnings-US$558.99m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-6.06
Gross Margin-37.80%
Net Profit Margin-106.93%
Debt/Equity Ratio248.3%

How did R2AR34 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/24 21:25
End of Day Share Price 2024/10/22 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Ultragenyx Pharmaceutical Inc. is covered by 37 analysts. 20 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jack AllenBaird
Michael UlzBaird
Huidong WangBarclays